Shaji Kumar, MD, Mayo Clinic, discusses the July approval of linvoseltamab, a new bispecific antibody for relapsed myeloma, and how it expands treatment options for patients. He also emphasizes the unique characteristics of linvoseltamab, such as its intravenous administration and flexible dosing schedule.
Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.
Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.
An expert discusses the 2025 NCCN guideline updates for ROS1-positive non-small cell lung cancer, highlighting the inclusion of taletrectinib and repotrectinib as preferred first-line therapies due to their high efficacy and CNS activity, the shift away from older agents like crizotinib and ceritinib, and the critical importance of early molecular testing to guide targeted treatment and avoid immunotherapy in this population.
Experts highlight that while universal screening for subclinical atrial fibrillation remains unsupported by current evidence, targeted screening of high-risk populations using data-driven approaches, combined with proactive management of cardiometabolic risk factors, offers a promising path to improve outcomes and optimize resource use.
Experts emphasize that remote patient monitoring (RPM) is most effective when supported by structured care teams and workflows, with artificial intelligence–enabled tools helping to interpret data and guide timely interventions—making RPM a vital component of personalized, proactive arrhythmia management.
Survivorship care and patient tools like the breast cancer index help patients and doctors curate an individualized survivorship plan for each patient.
Panelists discuss how health care providers need coordinated multidisciplinary care teams, visual resources like databases for eczema in skin of color, peer-to-peer educational sessions, and case-based learning to better recognize and manage atopic dermatitis (AD) across diverse skin tones.
Panelists discuss how treatment access challenges require provider advocacy through peer-to-peer reviews and patient assistance programs, whereas cost-effectiveness evaluation focuses on time to specialist care, therapy duration, and quality-of-life outcomes.
Olivo Adriana, NP, highlights the importance of survivorship care and how providers are utilizing available tools to the best of their ability.
An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, emphasizing RNA-based assays for detecting gene fusions, and stressing the importance of early molecular testing to guide targeted therapy selection and improve patient outcomes.
Panelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA), highlighting potential adverse effects and how these impact clinical decision-making.
Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and integration into the AA treatment algorithm, while addressing concerns around drug-to-drug interactions.
Experts highlight that well-integrated electronic health records and wearable devices can enhance diagnostic accuracy and patient engagement in arrhythmia care, while emphasizing the importance of combining technology with comprehensive clinical evaluation to guide efficient, personalized testing.
Experts discuss how choosing the right cardiac rhythm monitor involves balancing symptom frequency, patient risk, and device capabilities to ensure efficient, cost-effective, and patient-centered diagnosis while avoiding unnecessary testing.
Panelists discuss how biologic therapy selection depends on disease burden rather than just body surface area (BSA), with monitoring requiring objective measures, patient-reported outcomes, and specialized photography documentation for patients with darker skin tones.
Panelists discuss how patients with darker skin tones often experience delayed diagnosis due to misidentification as fungal infections or other conditions, emphasizing the importance of shared decision-making and patient education about the immune-mediated nature of the disease.
Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.
Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA).
Experts discuss how arrhythmia evaluation is tailored based on symptom frequency, severity, and patient risk, using a stepwise approach from short-term to extended monitoring to guide timely and effective diagnosis and management.
Experts discuss how rising arrhythmia burdens and workforce challenges are driving a shift toward team-based care, smarter diagnostics, and artificial intelligence–driven risk stratification to improve outcomes and efficiency.
Panelists discuss the critical role of effective follow-up and multidisciplinary care in managing hidradenitis suppurativa, emphasizing ongoing patient education, coordinated referrals, and personalized treatment plans to improve adherence and long-term outcomes.
Panelists discuss the importance of clear communication, financial support, and leveraging telehealth and peer networks to improve equitable access and adherence to specialized care and treatment for underserved patients with hidradenitis suppurativa.
Panelists discuss how atopic dermatitis (AD) presents differently across skin tones, appearing as purple, gray, or barely visible inflammation rather than classic redness, with perifollicular prominence and postinflammatory pigmentation changes being more prominent in patients with darker skin.
Panelists discuss how atopic dermatitis (AD) extends far beyond pruritus to include pain, sleep disturbances, psychosocial stigma, and quality-of-life impacts that affect patients’ work, school, and daily functioning regardless of disease severity.
Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments fail, though it can create a cost burden, and how beyond updated guidelines, there are unmet needs such as improved long-term treatments and better psychological support for patients.
Panelists discuss how the high failure rate of conventional treatments for long-standing, extensive alopecia areata (AA) may be due to factors such as disease chronicity and inadequate response to available therapies, and the need for key updates in AA management guidelines, which have not been revised since 2003.
Experts discuss the persistent clinical and systemic challenges in diagnosing and treating atrial fibrillation, emphasizing the need for earlier identification—especially in high-risk, comorbid populations—while highlighting the limitations of current risk models, the complexity of managing atrial fibrillation burden, and the importance of integrating wearable data into precision-based care without overburdening clinicians or compromising clinical relevance.
Experts discuss the multifaceted management of atrial fibrillation, stressing the importance of addressing comorbid conditions alongside the arrhythmia itself, while highlighting the challenges of underdiagnosis, the rise of subclinical cases detected through wearable technology, and the need to align emerging diagnostic tools with evidence-based care to avoid unnecessary interventions and optimize outcomes.
Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning, and leveraging resources—including clinical trials—to improve timely treatment and outcomes.
